Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

The role of the mitochondrial calcium uniporter (MCU) complex in cancer.

Vultur A, Gibhardt CS, Stanisz H, Bogeski I.

Pflugers Arch. 2018 Jun 21. doi: 10.1007/s00424-018-2162-8. [Epub ahead of print] Review.

PMID:
29926229
2.

Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma.

Liu S, Tetzlaff MT, Wang T, Chen X, Yang R, Kumar SM, Vultur A, Li P, Martin JS, Herlyn M, Amaravadi R, Li B, Xu X.

Oncotarget. 2017 Dec 5;8(70):115140-115152. doi: 10.18632/oncotarget.22944. eCollection 2017 Dec 29.

3.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

Cell Rep. 2017 Nov 14;21(7):1953-1967. doi: 10.1016/j.celrep.2017.10.021.

4.

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma.

Krepler C, Xiao M, Samanta M, Vultur A, Chen HY, Brafford P, Reyes-Uribe PI, Halloran M, Chen T, He X, Hristova D, Liu Q, Samatar AA, Davies MA, Nathanson KL, Fukunaga-Kalabis M, Herlyn M, Villanueva J.

Oncotarget. 2016 Nov 1;7(44):71211-71222. doi: 10.18632/oncotarget.12078.

5.

PIM kinases as therapeutic targets against advanced melanoma.

Shannan B, Watters A, Chen Q, Mollin S, Dörr M, Meggers E, Xu X, Gimotty PA, Perego M, Li L, Benci J, Krepler C, Brafford P, Zhang J, Wei Z, Zhang G, Liu Q, Yin X, Nathanson KL, Herlyn M, Vultur A.

Oncotarget. 2016 Aug 23;7(34):54897-54912. doi: 10.18632/oncotarget.10703.

6.

The promise of 3D skin and melanoma cell bioprinting.

Vultur A, Schanstra T, Herlyn M.

Melanoma Res. 2016 Apr;26(2):205-6. doi: 10.1097/CMR.0000000000000233. No abstract available.

PMID:
26925984
7.

The role of Orai-STIM calcium channels in melanocytes and melanoma.

Stanisz H, Vultur A, Herlyn M, Roesch A, Bogeski I.

J Physiol. 2016 Jun 1;594(11):2825-35. doi: 10.1113/JP271141. Epub 2016 Apr 6. Review.

8.

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.

Shannan B, Chen Q, Watters A, Perego M, Krepler C, Thombre R, Li L, Rajan G, Peterson S, Gimotty PA, Wilson M, Nathanson KL, Gangadhar TC, Schuchter LM, Weeraratna AT, Herlyn M, Vultur A.

Pigment Cell Melanoma Res. 2016 May;29(3):317-28. doi: 10.1111/pcmr.12465. Epub 2016 Mar 21.

9.

A stress-induced early innate response causes multidrug tolerance in melanoma.

Menon DR, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Rad EB, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H.

Oncogene. 2015 Aug 20;34(34):4545. doi: 10.1038/onc.2014.432. Epub 2015 Jan 26.

PMID:
25619837
10.

A stress-induced early innate response causes multidrug tolerance in melanoma.

Ravindran Menon D, Das S, Krepler C, Vultur A, Rinner B, Schauer S, Kashofer K, Wagner K, Zhang G, Bonyadi Rad E, Haass NK, Soyer HP, Gabrielli B, Somasundaram R, Hoefler G, Herlyn M, Schaider H.

Oncogene. 2015 Aug 20;34(34):4448-59. doi: 10.1038/onc.2014.372. Epub 2014 Nov 24. Erratum in: Oncogene. 2015 Aug 20;34(34):4545.

11.

Meeting report from the 10th International Congress of the Society for Melanoma Research, Philadelphia, PA, November 2013.

Vultur A, O'Connell M, Webster M, Villanueva J, Herlyn D, Somasundaram R, Krepler C, Zaidi R, Patton E, Sekulic A, Jonsson G, Weeraratna AT.

Pigment Cell Melanoma Res. 2014 Jul;27(4):E1-E12. doi: 10.1111/pcmr.12240. Epub 2014 May 6. No abstract available.

12.

Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, Indig FE, Flaherty KT, Wargo JA, Frederick DT, Cooper ZA, Nair S, Amaravadi RK, Schuchter LM, Karakousis GC, Xu W, Xu X, Weeraratna AT.

Cancer Discov. 2013 Dec;3(12):1378-93. doi: 10.1158/2159-8290.CD-13-0005. Epub 2013 Oct 8.

13.

Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.

Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, DeMarini DJ, Gilmer TM, Martin AM, Marmorstein R, Schultz DC, Speicher DW, Karakousis GC, Xu W, Amaravadi RK, Xu X, Schuchter LM, Herlyn M, Nathanson KL.

Cell Rep. 2013 Sep 26;4(6):1090-9. doi: 10.1016/j.celrep.2013.08.023. Epub 2013 Sep 19.

14.

Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.

Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Pätzold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, Hoth M, Bastian BC, Vogt T, Herlyn M.

Cancer Cell. 2013 Jun 10;23(6):811-25. doi: 10.1016/j.ccr.2013.05.003.

15.

SnapShot: melanoma.

Vultur A, Herlyn M.

Cancer Cell. 2013 May 13;23(5):706-706.e1. doi: 10.1016/j.ccr.2013.05.001. No abstract available.

16.

MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.

Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty PA, Wilson M, Hayden J, Keeney F, Nathanson KL, Herlyn M.

Oncogene. 2014 Apr 3;33(14):1850-61. doi: 10.1038/onc.2013.131. Epub 2013 Apr 29.

17.

Rhenium complexes with visible-light-induced anticancer activity.

Kastl A, Dieckmann S, Wähler K, Völker T, Kastl L, Merkel AL, Vultur A, Shannan B, Harms K, Ocker M, Parak WJ, Herlyn M, Meggers E.

ChemMedChem. 2013 Jun;8(6):924-7. doi: 10.1002/cmdc.201300060. Epub 2013 Apr 8.

18.

Highlights of the 2012 Congress of the Society for Melanoma Research, 8-11 November 2012, Hollywood, CA.

Vultur A, Webster M, Villanueva J, Herlyn D.

Melanoma Res. 2013 Jun;23(3):237-40. doi: 10.1097/CMR.0b013e3283610528.

PMID:
23546222
19.

The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.

Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT, Nathanson KL, Smalley KS, Herlyn M.

PLoS One. 2013;8(3):e59588. doi: 10.1371/journal.pone.0059588. Epub 2013 Mar 18.

20.

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y, Neiman EM, Benetatos C, Nathanson KL, Amaravadi RK, Pehamberger H, McKinlay M, Herlyn M.

Clin Cancer Res. 2013 Apr 1;19(7):1784-94. doi: 10.1158/1078-0432.CCR-12-2518. Epub 2013 Feb 12.

21.

Functional profiling of live melanoma samples using a novel automated platform.

Schayowitz A, Bertenshaw G, Jeffries E, Schatz T, Cotton J, Villanueva J, Herlyn M, Krepler C, Vultur A, Xu W, Yu GH, Schuchter L, Clark DP.

PLoS One. 2012;7(12):e52760. doi: 10.1371/journal.pone.0052760. Epub 2012 Dec 28.

22.

Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization.

Kong X, Qin J, Li Z, Vultur A, Tong L, Feng E, Rajan G, Liu S, Lu J, Liang Z, Zheng M, Zhu W, Jiang H, Herlyn M, Liu H, Marmorstein R, Luo C.

Org Biomol Chem. 2012 Sep 28;10(36):7402-17. doi: 10.1039/c2ob26081f.

23.

Identification of a novel family of BRAF(V600E) inhibitors.

Qin J, Xie P, Ventocilla C, Zhou G, Vultur A, Chen Q, Liu Q, Herlyn M, Winkler J, Marmorstein R.

J Med Chem. 2012 Jun 14;55(11):5220-30. doi: 10.1021/jm3004416. Epub 2012 May 18.

24.

Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options.

Villanueva J, Vultur A, Herlyn M.

Cancer Res. 2011 Dec 1;71(23):7137-40. doi: 10.1158/0008-5472.CAN-11-1243. Review.

25.

Organometallic Pyridylnaphthalimide Complexes as Protein Kinase Inhibitors.

Blanck S, Cruchter T, Vultur A, Riedel R, Harms K, Herlyn M, Meggers E.

Organometallics. 2011 Jul 18;30(17):4598-4606.

26.

Targeting BRAF in advanced melanoma: a first step toward manageable disease.

Vultur A, Villanueva J, Herlyn M.

Clin Cancer Res. 2011 Apr 1;17(7):1658-63. doi: 10.1158/1078-0432.CCR-10-0174. Epub 2011 Mar 29. Review.

27.

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M.

Cancer Cell. 2010 Dec 14;18(6):683-95. doi: 10.1016/j.ccr.2010.11.023.

28.

BRAF inhibitor unveils its potential against advanced melanoma.

Vultur A, Villanueva J, Herlyn M.

Cancer Cell. 2010 Oct 19;18(4):301-2. doi: 10.1016/j.ccr.2010.10.001.

29.

A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth.

Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A, Basu D, Gimotty P, Vogt T, Herlyn M.

Cell. 2010 May 14;141(4):583-94. doi: 10.1016/j.cell.2010.04.020.

30.

Beyond structure, to survival: activation of Stat3 by cadherin engagement.

Raptis L, Arulanandam R, Vultur A, Geletu M, Chevalier S, Feracci H.

Biochem Cell Biol. 2009 Dec;87(6):835-43. doi: 10.1139/o09-061. Review.

PMID:
19935869
31.

Cadherin-cadherin engagement promotes cell survival via Rac1/Cdc42 and signal transducer and activator of transcription-3.

Arulanandam R, Vultur A, Cao J, Carefoot E, Elliott BE, Truesdell PF, Larue L, Feracci H, Raptis L.

Mol Cancer Res. 2009 Aug;7(8):1310-27. doi: 10.1158/1541-7786.MCR-08-0469. Epub 2009 Aug 11.

32.

Stat3 activity is required for gap junctional permeability in normal rat liver epithelial cells.

Geletu M, Chaize C, Arulanandam R, Vultur A, Kowolik C, Anagnostopoulou A, Jove R, Raptis L.

DNA Cell Biol. 2009 Jul;28(7):319-27. doi: 10.1089/dna.2008.0833.

PMID:
19456249
33.

Cracking the system: melanoma complexity demands new therapeutic approaches.

Vultur A, Herlyn M.

Pigment Cell Melanoma Res. 2009 Feb;22(1):4-5. doi: 10.1111/j.1755-148X.2008.00527.x. Epub 2008 Dec 1. No abstract available.

PMID:
19054340
34.

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.

Buettner R, Mesa T, Vultur A, Lee F, Jove R.

Mol Cancer Res. 2008 Nov;6(11):1766-74. doi: 10.1158/1541-7786.MCR-08-0169.

35.

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.

Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R.

Mol Cancer Ther. 2008 May;7(5):1185-94. doi: 10.1158/1535-7163.MCT-08-0126.

36.

Electroporation of adherent cells in situ for the study of signal transduction and gap junctional communication.

Raptis L, Vultur A, Brownell HL, Tomai E, Anagnostopoulou A, Arulanandam R, Cao J, Firth KL.

Methods Mol Biol. 2008;423:173-89. doi: 10.1007/978-1-59745-194-9_12.

PMID:
18370198
37.

Examination of gap junctional, intercellular communication by in situ electroporation on two co-planar indium-tin oxide electrodes.

Anagnostopoulou A, Cao J, Vultur A, Firth K, Raptis L.

Mol Oncol. 2007 Sep;1(2):226-31. doi: 10.1016/j.molonc.2007.06.002. Epub 2007 Jun 20.

38.

Differential effects of c-Ras upon transformation, adipocytic differentiation, and apoptosis mediated by the simian virus 40 large tumor antigen.

Cao J, Arulanandam R, Vultur A, Anagnostopoulou A, Raptis L.

Biochem Cell Biol. 2007 Feb;85(1):32-48. Erratum in: Biochem Cell Biol. 2008 Apr;86(2):214-5. Biochem Cell Biol. 2007 Jun;85(3):395. Anagnostopoulu, Aikaterini [corrected to Anagnostopoulou, Aikaterini].

PMID:
17464343
39.

Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.

Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R.

Mol Cancer Ther. 2007 Apr;6(4):1400-5.

40.

Adenovirus E1A requires c-Ras for full neoplastic transformation or suppression of differentiation of murine preadipocytes.

Cao J, Arulanandam R, Vultur A, Anagnostopoulou A, Raptis L.

Mol Carcinog. 2007 Apr;46(4):284-302.

PMID:
17295229
41.

Differential effects of Stat3 inhibition in sparse vs confluent normal and breast cancer cells.

Anagnostopoulou A, Vultur A, Arulanandam R, Cao J, Turkson J, Jove R, Kim JS, Glenn M, Hamilton AD, Raptis L.

Cancer Lett. 2006 Oct 8;242(1):120-32. Epub 2005 Dec 27.

PMID:
16377083
42.

Stat3 is required for full neoplastic transformation by the Simian Virus 40 large tumor antigen.

Vultur A, Arulanandam R, Turkson J, Niu G, Jove R, Raptis L.

Mol Biol Cell. 2005 Aug;16(8):3832-46. Epub 2005 May 25.

43.

Adenovirus-5 E1A suppresses differentiation of 3T3 L1 preadipocytes at lower levels than required for induction of apoptosis.

Cao J, Arulanandam R, Vultur A, Preston T, Jaronczyk K, Tomai E, Zandi K, Raptis L.

Mol Carcinog. 2005 May;43(1):38-50.

PMID:
15768386
44.

Transfection techniques affecting Stat3 activity levels.

Arulanandam R, Vultur A, Raptis L.

Anal Biochem. 2005 Mar 1;338(1):83-9.

PMID:
15707938
45.

Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells.

Vultur A, Cao J, Arulanandam R, Turkson J, Jove R, Greer P, Craig A, Elliott B, Raptis L.

Oncogene. 2004 Apr 8;23(15):2600-16.

PMID:
15007380
46.

In situ electroporation of radioactive compounds into adherent cells.

Tomai E, Vultur A, Balboa V, Hsu T, Brownell HL, Firth KL, Raptis L.

DNA Cell Biol. 2003 May;22(5):339-46.

PMID:
12941161
47.

In situ electroporation of large numbers of cells using minimal volumes of material.

Raptis L, Balboa V, Hsu T, Vultur A, Turkson J, Jove R, Firth KL.

Anal Biochem. 2003 Jun 1;317(1):124-8. No abstract available.

PMID:
12729610
48.

Gap junctional intercellular communication in cells isolated from urethane-induced tumors in A/J mice.

Vultur A, Tomai E, Peebles K, Malkinson AM, Grammatikakis N, Forkert PG, Raptis L.

DNA Cell Biol. 2003 Jan;22(1):33-40.

PMID:
12590735
49.

Growth and isotopic labelling of adherent cells in small volumes of medium.

Vultur A, Keiski CL, Maynard M, Grammatikakis N, Raptis L.

J Virol Methods. 2002 Mar;101(1-2):207-10.

PMID:
11849699
50.

The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation.

Grammatikakis N, Vultur A, Ramana CV, Siganou A, Schweinfest CW, Watson DK, Raptis L.

J Biol Chem. 2002 Mar 8;277(10):8312-20. Epub 2001 Dec 20.

Supplemental Content

Loading ...
Support Center